ImmuPharma plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMMPF research report →
About the company
ImmuPharma plc, established in London, United Kingdom, in 1999, is a biopharmaceutical company dedicated to discovering and advancing peptide-based therapeutics. These treatments are focused on tackling conditions related to autoimmunity, inflammation, and various infections. The company's primary drug candidate, Lupuzor, an autophagy immunomodulator, is presently in Phase III clinical trials for the management of lupus, a chronic autoimmune inflammatory disorder.
- CEO
- Timothy Paul McCarthy XIV, FCCA, MBA
- IPO
- 2017
- Employees
- 14
- HQ
- London, GB
- Market Cap
- $28.34M
- P/E
- -5.60
- P/S
- 0.00
- P/B
- 24.82
- EV/EBITDA
- -4.17
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1397.44%
- ROIC
- -629.63%
- 52W High
- $0.09
- 52W Low
- $0.08
- 50D MA
- $0.09
- 200D MA
- $0.08
- Beta
- 1.41
- Avg Volume
- 0
Get TickerSpark's AI analysis on IMMPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IMMPF coverage
Recent articles, reports, and earnings notes.
No research on IMMPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMMPF report →Similar companies
Peers in the same neighborhood.